THE CLINICAL-SIGNIFICANCE OF HALOPEMIDE, A DOPAMINE-BLOCKER RELATED TO THE BUTYROPHENONES
THE CLINICAL-SIGNIFICANCE OF HALOPEMIDE, A DOPAMINE-BLOCKER RELATED TO THE BUTYROPHENONES
复制标题
DOI：
10.1159/000118141
复制
发表时间：
1984-01-01
影响因子：
3.2
通讯作者：
VERSTRAETEN, D
中科院分区：
文献类型：
--
作者：
DECUYPER, H;VANPRAAG, HM;VERSTRAETEN, D
在一项开放性研究和一项双盲研究中，对20例因各种精神疾病住院的患者进行了卤吡胺的再社会化和激活特性的研究。开放研究的结果显示，无论疾病分类学特征如何，接触和活动都有显著改善。单次（2 × 10 mg/天）和双倍（2 × 20 mg/天）剂量之间的治疗效果无显著差异。患者更容易接近，寻求与周围环境的接触，并对他们的工作表现出更大的兴趣。然而，这些结果未得到双盲研究的证实，双盲研究显示，安慰剂治疗期和卤培胺治疗期的这些目标症状无显著差异。两个因素可能解释的开放研究和双盲研究的结果之间的差异被假定：实验方法和研究阶段的持续时间短的差异。
The resocializing and activating properties of halopemide were investigated in an open study and a double-blind study in 20 patients who had been hospitalized on account of various psychiatric disorders. The results of the open study showed a significant improvement in contact and activity, regardless of the nosological characteristics. There was no significant difference in therapeutic effect between the single (2 x 10 mg/day) and the double (2 × 20 mg/day) dose. The patients were more approachable, sought contact with their surroundings and showed a greater interest in their work. However, these results were not confirmed by the double-blind study, which for these target symptoms showed no significant difference between the placebo phase and halopemide phase. Two factors that might explain the discrepancy between the results of the open study and the double-blind study are postulated: the difference in experimental methods and the short duration of the study phases.